For the year ending 2025-12-31, IBO had -$1,996K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -11,870 |
| Depreciation and amortization | 1,145 |
| Stock based compensation | 13 |
| Issuance of shares for professional services rendered | 190 |
| Accrued interest on notes payable | 793 |
| Change in deferred tax liability | -2,580 |
| Change in fair value of note payable, related party | 9,388 |
| Impairment of inventory | 419 |
| Loss on disposal of fixed assets | -12 |
| Accounts receivable | 1 |
| Inventory | -7 |
| Prepaid expenses and other current assets | -126 |
| Accounts payable | 470 |
| Accrued expenses | -2 |
| Net cash used operating activities | -1,890 |
| Payments received on notes receivable | 3 |
| Net cash provided by investing activities | 3 |
| Borrowings from related party | 184 |
| Payments to related party | 293 |
| Net cash (used) provided by financing activities | -109 |
| Net increase (decrease) in cash | -1,996 |
| Cash and cash equivalents at beginning of year | 1,999 |
| Cash and cash equivalents at end of year | 3 |
IMPACT BIOMEDICAL INC. (IBO)
IMPACT BIOMEDICAL INC. (IBO)